Teduglutide Patent Expiration

Teduglutide is Used for treating adult patients with short bowel syndrome who depend on parenteral support. It was first introduced by Takeda Pharmaceuticals Usa Inc in its drug Gattex Kit on Dec 21, 2012.


Teduglutide Patents

Given below is the list of patents protecting Teduglutide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Gattex Kit US5789379 Glucagon-like peptide-2 analogs Apr 14, 2015

(Expired)

Takeda Pharms Usa
Gattex Kit US5789379

(Pediatric)

Glucagon-like peptide-2 analogs Oct 14, 2020

(Expired)

Takeda Pharms Usa
Gattex Kit US7056886 GLP-2 formulations Sep 18, 2022

(Expired)

Takeda Pharms Usa
Gattex Kit US7056886

(Pediatric)

GLP-2 formulations Mar 18, 2023

(Expired)

Takeda Pharms Usa
Gattex Kit US7847061 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US7847061

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9060992 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9060992

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9539310 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9539310

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9545434 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9545434

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9545435 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9545435

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9555079 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9555079

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9572867 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9572867

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9592273 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9592273

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9592274 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9592274

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9968655 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9968655

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9968656 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9968656

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9968658 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9968658

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9974835 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9974835

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9974837 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9974837

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9981014 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9981014

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9981016 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9981016

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9987334 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9987334

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9987335 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9987335

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa
Gattex Kit US9993528 Treatment of short bowel syndrome patients with colon-in-continuity Nov 01, 2025 Takeda Pharms Usa
Gattex Kit US9993528

(Pediatric)

Treatment of short bowel syndrome patients with colon-in-continuity May 01, 2026 Takeda Pharms Usa


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳